Lantheus Holdings Inc. (LNTH) saw its stock price surge 5.07% during Monday's intraday trading session. The significant upward movement followed two key positive developments for the radiopharmaceutical company.

The primary catalyst was the announcement that Lantheus received tentative approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for Lutetium Lu 177 Dotatate (PNT2003). This product is a radioequivalent version of Novartis' LUTATHERA, used for treating somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors. Final approval is contingent on the expiration of patent litigation-related stays in June 2026.

Adding to the positive sentiment, Truist Securities raised its price target on Lantheus to $89 from $82 while maintaining a Buy rating on the shares. The combination of regulatory progress and analyst confidence contributed to the stock's strong performance in the market.